BioSyent Stock

BioSyent EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of BioSyent (RX.V) as of Sep 10, 2026 is 22.88 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was 21.92 % — a change of 4.41% (higher).

EBIT/Assets

22.88 %

YoY

4.41%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of BioSyent is 2026 22.88 % . Operating Income to Assets Ratio (EBIT/Assets) of BioSyent was 2025 21.92 % . It decreases by 4.41% higher compared to the previous year.

The BioSyent EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
21.79 CAD
Jan 1, 2019
17.40 CAD
Jan 1, 2020
14.98 CAD
Jan 1, 2021
22.02 CAD
Jan 1, 2022
17.25 CAD
Jan 1, 2023
18.14 CAD
Jan 1, 2024
21.92 CAD
Jan 1, 2025
22.88 CAD
The BioSyent EBIT/Assets history
YEAREBIT/AssetsYoY
22.88 %+4.41%
21.92 %+20.80%
18.14 %+5.20%
17.25 %-21.67%
22.02 %+46.95%
14.98 %-13.89%
17.40 %-20.13%
21.79 %-20.16%
27.29 %-8.71%
29.89 %-13.66%
34.62 %-13.38%
39.97 %
Access this data via the Eulerpool API

BioSyent Stock analysis

What does BioSyent do? Biosyent Inc is a Canadian pharmaceutical company founded in 2004. The company's headquarters are located in Mississauga, Ontario. Biosyent is listed on the Toronto Stock Exchange and has a market capitalization of approximately 140 million Canadian dollars. The company's business model is based on acquiring domestic pharmaceutical and nutraceutical products and marketing them in Canada. Biosyent operates in two main divisions: Pharma and Nutraceuticals. The Pharma division includes products such as RepaGyn, a vaginal gel for treating dryness and irritation during menopause, as well as the antiemetic Setofilm/Tablets for the prevention and treatment of nausea and vomiting. The Nutraceutical division includes products such as FeraMAX, a supplement that increases iron in the diet and helps prevent the development of anemia. Biosyent also offers vitamin-rich dietary supplements such as Aerobic Oxygen and Calm Biotic, targeting health-conscious customers. Another important area of Biosyent is Hospital Specialty Pharmaceuticals, targeting hospitals and healthcare facilities. This includes products like Cysview and Cysview Kit, used to detect non-muscle invasive bladder cancer and improve fluorescence during cystoscopy. Biosyent also offers infusion sets designed for intravenous medication administration. Overall, Biosyent has more than 20 products in various categories including women's and men's health, ophthalmology, immunology, and oncology. Over the years, Biosyent Inc has received various awards for its products and business practices. In 2012, the company received the Bio-Wellness Award for its flagship product, RepaGyn. While Biosyent has ambitions to expand its presence in international markets, the company remains primarily focused on the Canadian market. Biosyent relies mainly on a low-cost marketing strategy that aims to directly target patients in order to market its products in a simple way. Overall, Biosyent has a strong market position in Canada and a portfolio of well-established products. The company has a successful history and appears ready for the future with a strong pipeline and a growing presence in the Canadian market. BioSyent is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioSyent stock

Operating Income to Assets Ratio (EBIT/Assets) of BioSyent is 22.88 % in 2026.

Operating Income to Assets Ratio (EBIT/Assets) of BioSyent changed from 21.92 % to 22.88 %, representing a 4.41% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) BioSyent since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s BioSyent with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

Profitability — BioSyent

All Key Metrics — BioSyent